林业发展局授予AstraZeneca的IMFINZI优先审查权,用于高级膀胱癌治疗。 FDA grants Priority Review to AstraZeneca's IMFINZI for advanced bladder cancer treatment.

AstraZeneca的癌症药物IMFINZI(肾上腺素)已被林业发展局优先审查,以治疗肌肉侵入性膀胱癌患者。 AstraZeneca's cancer drug, IMFINZI® (durvalumab), has been given a Priority Review by the FDA for treating patients with muscle-invasive bladder cancer. 这是继其先前对肺癌的核准之后作出的。 This follows its previous approval for lung cancer. 由于优先审查地位赋予了在治疗严重病情方面可能大有改进的药物,预计决定会早些作出。 A decision is expected sooner due to the Priority Review status, which is granted to drugs that may offer significant improvements in treating serious conditions.